The Providers That Got Better (and Worse) Since Our Last Review
Provider comparisons that never get updated are one of the biggest sources of stale, misleading information in this space — pricing changes, policies shift, and a platform that was solid a year ago isn't guaranteed to still be. Here's our accountability update, comparing what's changed.
Why most comparison content gets this wrong
A lot of "best GLP-1 provider" articles are published once and never revisited, even as the providers listed change their pricing, ownership, or clinical standards. That's not just laziness — it actively misleads readers who assume a review reflects current reality.
What we're tracking
- Pricing changes — both increases and decreases since our last review cycle
- Clinical process changes — has intake gotten more or less thorough?
- Regulatory actions — any new FDA warning letters or state AG actions since our last check
- Policy changes — cancellation terms, subscription structures, refund policies
Embody From consult
Consistently documented clinical review process across our tracking period.
Visit Embody →Paid linkDirect Meds From consult
Confirm current pricing and terms directly, as this space changes frequently.
Why we commit to this
A provider comparison that never updates is a static snapshot pretending to be current information. We revisit our rankings and flag material changes specifically so you're not making a decision based on outdated data — and we're transparent when something we recommended has gotten worse, not just when something new looks better.